A Study to Investigate the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injections of PG-102 (MG12) in Healthy Adult and Obesity Participants.

NCT06309667 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

102

Enrollment

OTHER

Sponsor class

Conditions

Healthy
Overweight

Interventions

DRUG: PG-102(MG12)
OTHER: Placebo

Sponsor

ProGen. Co., Ltd.